GeneFerm Biotechnology Co., Ltd. (TPEX:1796)
Taiwan · Delayed Price · Currency is TWD 44.85
+0.05 (0.11%)
Jan 22, 2026, 1:30 PM CST
GeneFerm Biotechnology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 654.88 | 521.16 | 793.77 | 633.96 | 522.33 | 368.3 | Upgrade | |
Revenue Growth (YoY) | 19.26% | -34.34% | 25.21% | 21.37% | 41.82% | 12.21% | Upgrade |
Cost of Revenue | 491.65 | 424.42 | 507.42 | 411.8 | 329.68 | 246.32 | Upgrade |
Gross Profit | 163.23 | 96.75 | 286.35 | 222.16 | 192.65 | 121.98 | Upgrade |
Selling, General & Admin | 108.69 | 102.93 | 104.88 | 96.71 | 88.82 | 81.53 | Upgrade |
Research & Development | 32.96 | 29.31 | 28.33 | 24.18 | 23.56 | 22.41 | Upgrade |
Operating Expenses | 142.08 | 131.15 | 132.79 | 120.17 | 113.82 | 104.86 | Upgrade |
Operating Income | 21.15 | -34.41 | 153.57 | 101.99 | 78.84 | 17.12 | Upgrade |
Interest Expense | -5.89 | -4.44 | -4.17 | -3.82 | -7.32 | -9.83 | Upgrade |
Interest & Investment Income | 1.54 | 1.54 | 0.92 | 0.33 | 0.21 | 0.18 | Upgrade |
Currency Exchange Gain (Loss) | -7.88 | 4.8 | 0.84 | 9.66 | -2.67 | -3.08 | Upgrade |
Other Non Operating Income (Expenses) | 5.45 | 5.03 | 2.27 | 2.6 | 1.51 | 1.94 | Upgrade |
EBT Excluding Unusual Items | 14.37 | -27.49 | 153.42 | 110.76 | 70.57 | 6.33 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | -0.43 | - | - | Upgrade |
Gain (Loss) on Sale of Assets | -0.26 | 0.02 | 0.01 | -0.11 | 0.04 | 0.44 | Upgrade |
Other Unusual Items | - | - | - | - | -0.21 | - | Upgrade |
Pretax Income | 14.11 | -27.47 | 153.43 | 110.21 | 70.4 | 6.77 | Upgrade |
Income Tax Expense | -1.96 | -4.94 | 28.81 | 16.76 | 12.98 | 2.24 | Upgrade |
Net Income | 16.07 | -22.53 | 124.62 | 93.45 | 57.41 | 4.53 | Upgrade |
Net Income to Common | 16.07 | -22.53 | 124.62 | 93.45 | 57.41 | 4.53 | Upgrade |
Net Income Growth | - | - | 33.35% | 62.78% | 1167.67% | - | Upgrade |
Shares Outstanding (Basic) | 41 | 41 | 41 | 41 | 40 | 28 | Upgrade |
Shares Outstanding (Diluted) | 41 | 41 | 42 | 43 | 46 | 28 | Upgrade |
Shares Change (YoY) | 0.03% | -0.36% | -2.26% | -8.00% | 65.83% | 0.19% | Upgrade |
EPS (Basic) | 0.39 | -0.54 | 3.01 | 2.26 | 1.45 | 0.16 | Upgrade |
EPS (Diluted) | 0.39 | -0.54 | 2.99 | 2.20 | 1.32 | 0.16 | Upgrade |
EPS Growth | - | - | 35.63% | 66.87% | 725.71% | - | Upgrade |
Free Cash Flow | 85.39 | -14.31 | 120.37 | -155.74 | -32.65 | -25.9 | Upgrade |
Free Cash Flow Per Share | 2.06 | -0.34 | 2.89 | -3.66 | -0.70 | -0.93 | Upgrade |
Dividend Per Share | - | - | 2.000 | 1.500 | 1.000 | 0.083 | Upgrade |
Dividend Growth | - | - | 33.33% | 50.00% | 1103.93% | - | Upgrade |
Gross Margin | 24.92% | 18.56% | 36.08% | 35.04% | 36.88% | 33.12% | Upgrade |
Operating Margin | 3.23% | -6.60% | 19.35% | 16.09% | 15.09% | 4.65% | Upgrade |
Profit Margin | 2.45% | -4.32% | 15.70% | 14.74% | 10.99% | 1.23% | Upgrade |
Free Cash Flow Margin | 13.04% | -2.74% | 15.17% | -24.57% | -6.25% | -7.03% | Upgrade |
EBITDA | 89.79 | 37.89 | 219.41 | 145.16 | 117.76 | 51.63 | Upgrade |
EBITDA Margin | 13.71% | 7.27% | 27.64% | 22.90% | 22.55% | 14.02% | Upgrade |
D&A For EBITDA | 68.64 | 72.3 | 65.84 | 43.16 | 38.92 | 34.51 | Upgrade |
EBIT | 21.15 | -34.41 | 153.57 | 101.99 | 78.84 | 17.12 | Upgrade |
EBIT Margin | 3.23% | -6.60% | 19.35% | 16.09% | 15.09% | 4.65% | Upgrade |
Effective Tax Rate | - | - | 18.78% | 15.21% | 18.44% | 33.09% | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.